Comparison 5. Gemcitabine versus one‐third dose Bacillus Calmette‐Guérin (BCG).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Time to recurrence	1	118	Hazard Ratio (IV, Random, 95% CI)	1.17 [0.57, 2.42]
5.2 Time to progression	1	118	Hazard Ratio (IV, Random, 95% CI)	1.63 [0.39, 6.83]
5.3 Grade III–V adverse events	1	88	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
5.4 Grade I or II adverse events	1	88	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.49, 1.46]
5.5 Disease‐specific quality of life	1	88	Mean Difference (IV, Random, 95% CI)	4.50 [‐1.60, 10.60]